As a CD40 ligand antagonist, dazodalibep blocks immune cell communication, potentially serving as the first drug to target the autoimmune disease’s cause.
N-cadherins in smooth muscle cells play an important role in constricting bronchi, but inhibiting the protein could provide relief to patients with asthma.
Bristol Myers Squibb unveiled promising CAR T cell therapy data for severe autoimmune diseases from their Phase 1 clinical trial, offering hope for remission.